HIMS Stock Rallies 67% in Q2, Analysts Split Between $40 Bull and $21 Bear Case

According to Benzinga, on July 1, 2026, Hims & Hers Health stock traded near $37.36 after a 67% gain in the second quarter of 2026. The 13-analyst average price target sits at $28.35–$30.14, roughly 20% below the current price, yet the bull case from Canaccord Genuity stands at $40 while the street low hits $21, creating a wide 44% downside spread.

The FDA's Peptide Compounding Advisory Committee meets July 23–24 with a formal recommendation against compounding certain peptides. Monthly sales growth accelerated from mid-single digits in April to high-teens by June, driven by the launch of generic semaglutide in Canada and the Eucalyptus acquisition closing in early June.